

PROSPECTIVE STUDY ON RESTRICTED-USE ANTIBIOTICS: ertapenem, linezolid, tigecycline and daptomycin



C. Ramírez Roig, J. Velasco Costa, R. Olmos Jiménez, J. Mateo Carmona, L. Menendez Naranjo, MC. Muñoz Contreras, A. De la Rubia Nieto.

University Hospital Arrixaca, Pharmacist, Murcia, Spain.

PURPOSE

To analyze the appropriateness of the use of restricted use antibiotics approved by the Pharmacy and Therapeutics Committee (DTC).

MATERIALS AND METHODS



100 PATIENTS

- 39% Ertapenem
- 7% Tigecycline
- 49% Linezolid
- 5% Daptomycin

VARIABLES

- Age
- Laboratory data
- Clinical Service
- Justification of the indication
- Duration of treatment

RESULTS



	ERTAPENEM	TIGECYCLINE	LINEZOLID	DAPTOMYCIN
Duration of treatment (days)	4,5	12,5	12,5	18
Adequacy (%)	92,3	85,71	83,6	60

CONCLUSION

- 1) The appropriateness of the use of restricted antibiotics as approved by the DTC, although acceptable, could be improve.
- 2) The participation of pharmacists in choosing the most appropriate treatment strategy and drug for the patient, could improve the use of restricted use antibiotics.
- 3) An antibiotic control program between the Pharmacy and Infectious Disease departments could improve patient care quality.

